
What smart money is saying about RadNet, Inc.
2 funds in our archive have pitched RadNet, Inc., most recently Baron Health Care Fund in September 2026.
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2024 and Q3 2026, 2 fund letters reported a position in RadNet, Inc., with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1 | 1 |
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 1 move
- TrimmedBaron Health Care FundSeptember 2026
“Top net sales for the quarter Net Amount Sold ($M) AstraZeneca PLC 2.4 Madrigal Pharmaceuticals, Inc. 2.3 Gilead Sciences, Inc. 2.3 BillionToOne, Inc. 2.3 RadNet, Inc. 1.5 We sold AstraZeneca PLC for the reasons discussed earlier. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor’s clinical trial readout. We sold Gilead Sciences, Inc. because of concerns about slowing growth of key growth driver Yeztugo. We reduced the positions in BillionToOne, Inc. and RadNet, Inc. due to valuation, though we maintain conviction in both companies.”
RadNet, Inc. - June 2026
Listed in Baron Health Care Fund’s reported holdings.
RadNet, Inc.
Fund coverage · 2 theses
- Baron Health Care FundSeptember 2026
RadNet, Inc. operates outpatient diagnostic imaging centers and is supported by secular growth in advanced imaging, new clinical indications, capacity expansion, and AI-enabled technology.
Read the full thesis - Clearbridge SMid Cap Growth StrategyDecember 2024
RadNet is a growing player in the health care sector, benefiting from a shift to freestanding diagnostic imaging centers, with growth potential through geographic expansion and AI applications.
Read the full thesis
Read every full thesis on RadNet, Inc.
Read all 2 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→